ArticlePloS one2009
Generation of monoclonal antibodies against highly conserved antigens.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- To generate functional anti-protease-activated receptor-4 (PAR4), a G protein-coupled receptor, antibodies through PAR4-mRNA-LNP immunization.NPJ vaccines · 2025Article
- Article
- Development and characterization of an ETV1 rabbit monoclonal antibody for the immunohistochemical detection of ETV1 expression in cancer tissue specimens.Journal of immunological methods · 2023Article
- HMGB1 from Astrocytes Promotes EAE by Influencing the Immune Cell Infiltration-Associated Functions of BMECs in Mice.Neuroscience bulletin · 2022Article
- Monoclonal Antibodies Generation: Updates and Protocols on Hybridoma Technology.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Association of insulin-like growth factor 1 (IGF1) gene polymorphism with the reproductive performance of three dual-purpose chicken breeds.Translational animal science · 2021Article
- Article
- Sialoglycan recognition is a common connection linking acidosis, zinc, and HMGB1 in sepsis.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Unraveling the sugar code: the role of microbial extracellular glycans in plant-microbe interactions.Journal of experimental botany · 2021Review
- HMGB1 participates in LPS‑induced acute lung injury by activating the AIM2 inflammasome in macrophages and inducing polarization of M1 macrophages via TLR2, TLR4, and RAGE/NF‑κB signaling pathways.International journal of molecular medicine · 2020Article
- Ethyl pyruvate reduces organic dust-induced airway inflammation by targeting HMGB1-RAGE signaling.Respiratory research · 2019Article
- Enhancers Improve the AID-Induced Hypermutation in Episomal Vector for Antibody Affinity Maturation in Mammalian Cell Display.Antibodies (Basel, Switzerland) · 2018Article
- Strategies for Generating Diverse Antibody Repertoires Using Transgenic Animals Expressing Human Antibodies.Frontiers in immunology · 2018Article
- Development of novel monoclonal antibodies against starch and ulvan - implications for antibody production against polysaccharides with limited immunogenicity.Scientific reports · 2017Article
- Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.Cancer discovery · 2017Article
- Generation of potent mouse monoclonal antibodies to self-proteins using T-cell epitope "tags".mAbs · 2015Article
- Suppression of breast tumor growth by DNA vaccination against phosphatase of regenerating liver 3.Gene therapy · 2013Article
- Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors.The Journal of biological chemistry · 2012Article
- Article
- Mammalian target of rapamycin activation underlies HSC defects in autoimmune disease and inflammation in mice.The Journal of clinical investigation · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTherapeutic antibody development is one of the fastest growing areas of the pharmaceutical industry. Generating high-quality monoclonal antibodies against a given therapeutic target is very crucial for the success of the drug development. However, due to immune tolerance, some proteins that are highly conserved between mice and humans are not very immunogenic in mice, making it difficult to generate antibodies using a conventional approach. METHODOLOGY/PRINCIPAL
findingsIn this report, the impaired immune tolerance of NZB/W mice was exploited to generate monoclonal antibodies against highly conserved or self-antigens. Using two highly conserved human antigens (MIF and HMGB1) and one mouse self-antigen (TNF-alpha) as examples, we demonstrate here that multiple clones of high affinity, highly specific antibodies with desired biological activities can be generated, using the NZB/W mouse as the immunization host and a T cell-specific tag fused to a recombinant antigen to stimulate the immune system. CONCLUSIONS/SIGNIFICANCE: We developed an efficient and universal method for generating surrogate or therapeutic antibodies against "difficult antigens" to facilitate the development of therapeutic antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.